A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE3

Conditions

Secondary Progressive Multiple Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States

  • Perseverance Research Center, LLC (PRC), Scottsdale, Arizona, United States

  • Fullerton Neurology and Headache Center, Fullerton, California, United States

  • Regina Berkovich MD, PhD Inc, West Hollywood, California, United States

  • SFM Clinical Research, LLC, Boca Raton, Florida, United States

  • Nova Clinical Research, LLC, Bradenton, Florida, United States

  • MS and Neuromuscular Center of Excellence, Clearwater, Florida, United States

  • Neurology Associates, Maitland, Florida, United States

  • Josephson Wallack Munshower Neurology, Pc Suite 225, Indianapolis, Indiana, United States

  • KC Research Center, PA Neurology Research Dept, Roeland Park, Kansas, United States

  • Boston Clinical Trials, Boston, Massachusetts, United States

  • Profound Research LLC at Oakland Neurology Center, Rochester Hills, Michigan, United States

  • Washington University School of Medicine, St Louis, Missouri, United States

  • The Boster Center for Multiple Sclerosis, Columbus, Ohio, United States

  • OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, United States

  • Premier Neurology, Greenville, South Carolina, United States

  • Lone Star Neurology, San Antonio, Texas, United States

  • Texas Institute for Neurological Disorders - Sherman, Sherman, Texas, United States